Login
Greater Cannabis Company Inc logo

Greater Cannabis Company Inc

gcanrx.com

What Do They Do?

Develops cannabinoid therapeutics, including a licensed treatment program for neuropsychiatric disorders.

How Do They Make Money?

FY2021 revenue

Do Revenues Turn Into Profits?

No. It lost $602.2K in FY2021.

Operating income, FY2021
−2717% of revenue
▲ +17% (Loss) vs FY2020 (−$294.5K, −613%)
Net income, FY2021
−4768% of revenue
▼ −37% (Loss) vs FY2020 (−$951.2K, −1980%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
Net income
▲ Now profitable
vs −$390.9K in Q2 FY2025
  • Jul 31, 2026 Appointed a new chief financial officer Michelle Cervantes Vivanco was appointed CFO; Porfirio Sanchez Talavera remained CEO and chair.
  • Jul 6, 2026 Trafalgar Asset Management acquired voting control It gained control through purchases of the company’s Series A and Series B preferred shares; Porfirio Sanchez Talavera became CEO and chair.

Shrinking. Revenue fell 87% in 3 years, from $95.4K in FY2018 to $12.6K in FY2021, about 49% a year.

Narrowed business focus The older report paired cannabinoid-therapy development with cannabis-related investment and deal opportunities; the latest describes therapeutic development and commercialization and says the company no longer intends direct investment operations.

Who Do They Compete With?

Competes with Jazz Pharmaceuticals and Zynerba Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support